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The immune substances . . . in the manner 
ofmagic bullets, seek out the enemy 
Paul Ehrlich 
The principle of targeting drugs to specific cells as 
weapons for selective killing of malignant and other 
disease-causing cells goes back nearly 100 years. In 
1906, Paul Ehrlich predicted the construction of 
‘magic bullets’ (Zauberkugeln) as ‘bodies which possess 
a particular affinity for a certain organ . . . as a carrier 
by which to bring therapeutically active groups to the 
organ in question’ [l]. 
Over the past 25 years, the confluence of the 
discovery and applications of monoclonal antibodies, 
the progress in protein toxin research, the applications 
of recombinant DNA methodologies, and genetic and 
protein engineering, have allowed Ehrlich’s goal to be 
realized. 
In this respect, a great number of experimental and 
clinical investigations were and are still developed with 
chemically or genetically engineered chimeric (hybrid) 
molecules in which various cell-binding ligands (parti- 
cularly immunoglobulins) were coupled to highly 
cytotoxic protein toxins (or their subunits) to generate 
chemotherapeutic agents to specifically kill malignant, 
virus-infected (e.g. HIV, HTLV) or other potentially 
pathogenic host cells (see references 2-9 for reviews). 
Toxin moieties of the conjugates 
Many protein toxins of bacterial or plant origin 
endowed with potent cytotoxic properties towards 
eukaryotic cells have been evaluated. The most com- 
monly used bacterial toxins to generate appropriate 
hybrids for experimental purposes and/or clinical trials 
are diphtheria toxin [4-8,10-13] and Pseudomonas 
aeruginosa exotoxin A [4-7,14,15]. 
Both toxins kill target cells by the same molecular 
mechanism. After binding to host cells they are 
internalized and their respective active moieties 
(fragment A) are translocated into the cell cytosol, 
where they ADP-ribosylate elongation factor 2 (EF2) 
and thereby inhibit protein synthesis, leading to cell 
death [5-71. 
The plant toxins ricin and to a lesser extent abrin 
have also been used [6,8,16-191. These two-chain 
toxins inhibit protein synthesis by inactivating the 28s 
R N A  of eukaryotic cells [4-61. The ricin-like single- 
chain gelonin was also used as a chimeric conjugate 
for in vivo treatment of experimental Heymann’s 
nephritis in rats [20]. Another conjugate based on the 
membrane-damaging toxin perfringolysin 0 was also 
used as an experimental cell killer [21]. 
Cell-binding ligands of the conjugates 
The ligands to be coupled to the bioactive toxin 
moieties belong to various families. The most com- 
monly used targeting agents since 1975 are monoclonal 
antibodies generated against tumor-associated antigens 
or certain T- and B-lymphocyte or natural killer (NK) 
cell surface antigens (CD2,11,18,22,30,33). These 
hybrids were designed to kill hematopoietic and tumor 
cells or HIV-infected T-cells, or to treat autoimmune 
diseases (e.g. rheumatoid arthritis, diabetes) [7,8]. The 
antibody-toxin conjugates constitute the so-called 
immunotoxins (IT). The first generation of ITS was 
composed of whole IgG antibodies chemically con- 
jugated to the above mentioned protein toxins. Due to 
the large size ofthe antibody molecule (150 kDa), poor 
tumor penetration was obtained. This and other 
problems were overcome by the design of the second- 
generation ITS based on antibody engineering and 
recombinant DNA techniques with a concomitant 
increase in tumor penetration potential. These novel 
recombinant ITS contained only the 25-kDa Fv 
heterodimer of the heavy and light chains of the 
antibody conjugated to the appropriate toxin moiety 
by either a peptide linker (ScFv) or a disulfide bond 
(dsFv). 
Members of the other class of hybrid molecules to 
be targeted to disease-causing cells do not include 
antibodies or Fv fragments. The chimeric agents are 
generated by replacing (by gene fusion methodologies) 
the native cell-binding domains of the appropriate 
bacterial or plant toxins with various effectors such as: 
transforming growth factor-a (TGF-a), which targets 
epidermal growth factor receptors on many types of 
malignant cells; a-melanocyte-stimulating hormone 
(a-MSH), which targets a-MCH receptor on melanoma 
cells; and IL-2, IL-6, IL-15 and GM-CSF in the therapy 
of various hematologic malignancies and psoriasis 
[5,7,8:11,22,23]. 
Conclusions 
The considerable experimental and clinical investigations 
based on toxin-fusion ligands are quite impressive. New 
improvements in the development of safe and effective 
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chimeric molecules will probably lead to a new class of 
therapeutic agents against severe diseases. 
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